1 BTC
=
- USD
Mural Oncology plc Ordinary Shares
As of May 30, 2026 at 24:05 UTC
Chart
About Mural Oncology plc Ordinary Shares
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Market Statistics
Trading Metrics
How to Buy MURA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MURA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesMural Oncology has completed a scheme of arrangement with XOMA Royalty, where XOMA will acquire the entire issued share capital of Mural. The transaction became effective on December 5, 2025, with share trading cancellation and shareholder consideration distribution expected soon.
Mural Oncology has received High Court approval for a scheme of arrangement where XOMA Royalty will acquire the entire share capital of Mural. The acquisition is expected to become effective on December 5, 2025, with Mural shares to be delisted from Nasdaq on December 4, 2025.
Mural Oncology announced the final details of its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with a total cash consideration of $2.035 per share. The acquisition is expected to close in early December 2025, subject to Irish High Court sanction.
